Disclosure of Relevant Financial Relationships with Commercial Interests

USF Health endorses the standards of the ACCME and all applicable accrediting organizations that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Authors

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Contravir, Gilead Sciences, and Merck and funds for research support from AbbVie, Gilead Sciences, Janssen, and Merck. Dr. Feld disclosed in previous editions that he had received consulting fees from Abbott, Bristol-Myers Squibb, Janssen, and Theravance and funds for research support from Boehringer Ingelheim and Santaris.

Hemant Shah, MD, MScCH HPTE

Assistant Professor
Faculty of Medicine
University of Toronto
Hepatology/Gastroenterology
Toronto Centre for Liver Disease
University Health Network
Toronto, Canada

Hemant Shah, MD, MScCH HPTE, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Intercept. Dr. Shah disclosed in previous editions that he had received consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Hoffmann-La Roche, Janssen, Merck, and Vertex; had served on advisory boards or panels for Vertex; and had received funds for research support from the Ministry of Health.

Editor In Chief

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has served as a consultant and has received fees for non-CME/CE services from AbbVie, Gilead Sciences, and Merck. Dr. Zeuzem has disclosed in previous editions that he had served as a consultant or on advisory boards for Abbott, AbbVie, Achillion, Anadys, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, iTherX, Janssen, Merck, Novartis, Pfizer, Pharmasset, Presidio, Roche, Santaris, Tibotec/Janssen, and Vertex and had served on speaker bureaus for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Roche.

Staff

Edward King, MA

Executive Vice President

Edward King, MA, has no real or apparent conflicts of interest to report.

Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no real or apparent conflicts of interest to report.

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

USF Health OCPD staff members and the peer/content reviewers for this activity have no relevant financial relationships to disclose. Disclosures are on file at the USF Health Office of Continuing Professional Development.

Additional Disclosure Information

The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Nezam H. Afdhal, MD, FRCPI, disclosed that he had served as a consultant or on advisory boards for AbbVie, Achillion, Biogen, Biolex, Boehringer Ingelheim, Echosens, FibroGen, Gilead Sciences, GlaxoSmithKline, Idera, Janssen, Kadmon, Ligand, Medgenics, Merck, Novartis, Sandhill Scientific, Spring Bank, and Vertex; had received funds for research support from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Quest, and Vertex; and had stock options for Medgenics and Spring Bank at the time he contributed to this module.

Anna Poppa disclosed that she had received consulting fees from ViiV at the time she contributed to this module.

Heather Stieglitz, PhD; Deanna M. Heier, PhD; Michael Westhafer, MD; and Sheralee Connors, MA, had no real or apparent conflicts of interest to report at the time they contributed to this module. 

Marc Bourlière, MD, disclosed that he had received consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche, and Vertex at the time he contributed to this module.

Maria Buti, MD, disclosed that she had received consulting fees from Boehringer Ingelheim, Gilead Sciences, Janssen, and Merck at the time she contributed to this module.

Graham R. Foster, FRCP, PhD, disclosed that he had received consulting fees and fees for non-CME services from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Novartis, and Roche and funds for research support from Janssen and Roche at the time he contributed to this module.

Donald M. Jensen, MD, disclosed that he had received consulting fees from Abbott, Astex, Biotica, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Janssen, Merck, and Vertex at the time he contributed to this module.

Leonard B. Seeff, MD, disclosed that he was a consultant in hepatology for The Hill Group in Bethesda, Maryland at the time he contributed to this module, and a former senior scientist for hepatitis research at the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health.

Eric Lawitz, MD, CPI, disclosed that he had received funds for research support from AbbVie, Achillion, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Idenix, Intercept, Janssen, Medtronic, Merck, Novartis, Presidio, Roche, Santaris, and Vertex; had received speaker’s fees from Gilead Sciences, Kadmon, Merck, and Vertex; had served as a member of the advisory boards for AbbVie, Achillion, BioCryst, Biotica, Enanta, Idenix, Janssen, Merck, Novartis, Santaris, Theravance, and Vertex at the time he contributed to this module.

Alessandra Mangia, MD, had no real or apparent conflicts of interest to report at the time she contributed to this module.

Norah Terrault, MD, MPH, disclosed that she had served as a consultant for Biotest, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche/Genentech, and Siemens and had received funds for research support from Eisai, Gilead Sciences, Novartis, Roche/Genentech, and Vertex at the time she contributed to this module.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Unapproved Use Disclosure

USF Health requires CME faculty to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

USF Health Privacy Policy

USF Health Office of Continuing Professional Development (OCPD) has created a privacy policy to demonstrate our commitment to guarding the privacy of our clients. The following statements disclose our practices on gathering and disseminating information for this web site. The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual’s contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

If you have any questions about this privacy policy, please contact USF Health OCPD, at cpdsupport@health.usf.edu.

Equal Opportunity

USF is an Equal Opportunity/ Equal Access/ Affirmative Action Institution.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries, please contact: cpdsupport@health.usf.edu.

inPractice Hepatology current certification period
Release Date: January 1, 2019
Expiration Date: June 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with viral hepatitis.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support

This program is supported by educational grants from AbbVie and Gilead Sciences.


inPractice HIV current certification period
Release Date: September 26, 2019
Expiration Date: September 25, 2020

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

Commercial Support:

This program is supported by educational grants from Gilead Sciences and ViiV Healthcare.


For inPractice Hepatology

Physician Continuing Medical Education (for Point of Care CME activities)
USF University

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and inPractice Resources. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF

USF Health designates this internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 CreditTM .Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For inPractice HIV

Physician Continuing Medical Education (for Point of Care CME activities)
CCO

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CCO designates this internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Credit (Point of Care CME)

inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:

  1. Register online at http://www.inpractice.com
  2. Execute a search or submit a clinical question
  3. Review the applicable clinical sources
  4. Click the "Claim CME Credit" button at the top right corner of the content you have viewed
  5. Complete the simple evaluation questions addressing clinical application of learnings from the sources you have consulted

After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.